Syensqo has launched a strategic review of its Performance & Care segment, aiming to focus more on specialty materials and advanced technologies in high-growth markets like aerospace, healthcare, and energy. The review seeks to sharpen capital allocation, accelerate growth, and maximize shareholder value. The segment generated €2.0 billion in sales and €358 million EBITDA in 2025. No timeline or guarantee of a transaction has been set yet, with updates to follow as appropriate.
Liminatus Pharma's stock surged 79.34% in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal will bring a clinical-stage oncology portfolio to Liminatus, including a CAR-T therapy candidate aut...
BTS Group AB reported a return to profitable growth in Q1 2026, with net sales of 602 million SEK, a 5% increase adjusted for currency effects, including 2% organic growth. EBITA rose 5% to 62 million SEK, improving the EBITA margin to 10.3% from 9.1...
Futurionex Blockchain Trading Ltd. has launched an update to its AI Quant 2.0 system, enhancing high-frequency trading execution to improve efficiency from strategy signals to order completion. This upgrade allows faster data capture and order execut...
Futurionex has enhanced its AI Quant 2.0 platform by integrating high-frequency execution capabilities, improving the speed and efficiency of converting trading strategy signals into actual trades. This upgrade addresses the critical need for rapid o...
Stellantis presented its new strategic plan at Investor Day 2026, held at its Michigan headquarters and broadcast live. CEO Antonio Filosa shared the company's long-term vision and strategic direction with investors, analysts, and media. The event ma...
